Skip to main content

NKTR research · 13F holders by reporting quarter

Nektar Therapeutics (NKTR): 13F holders, 2026Q2

The largest share positions in NKTR that the managers Kresmion follows reported on Form 13F for 2026Q2, as filed. The current quarter, the company's SEC filings and its recent events are on the NKTR research page.

NKTR positions held by the managers we follow (2026Q2)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
TWO SIGMA INVESTMENTS, LP FundCUSIP 640268306 · 2026Q2$83.9M0.06%
MILLENNIUM MANAGEMENT LLC FundCUSIP 640268306 · 2026Q2$33.4M0.02%
CITADEL ADVISORS LLC FundCUSIP 640268306 · 2026Q2$11.2M0.01%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.